AR097404A1 - MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN GPA33 AND CD3, AND USES OF THE SAME - Google Patents
MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN GPA33 AND CD3, AND USES OF THE SAMEInfo
- Publication number
- AR097404A1 AR097404A1 ARP140103130A ARP140103130A AR097404A1 AR 097404 A1 AR097404 A1 AR 097404A1 AR P140103130 A ARP140103130 A AR P140103130A AR P140103130 A ARP140103130 A AR P140103130A AR 097404 A1 AR097404 A1 AR 097404A1
- Authority
- AR
- Argentina
- Prior art keywords
- gpa33
- diabodies
- bispecific monovalent
- monovalent
- epitope
- Prior art date
Links
- 102100034231 Cell surface A33 antigen Human genes 0.000 title 1
- 101000996823 Homo sapiens Cell surface A33 antigen Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se dirige a diacuerpos monovalentes biespecíficos que comprenden dos cadenas de polipéptidos y los cuales poseen al menos un sitio que une de manera especifica a un epítopo de CD3 y un sitio que une de manera específica a un epítopo de gpA33 (es decir, un diacuerpo monovalente biespecífico de gpA33 x CD3). La presente también se dirige a diacuerpos monovalentes biespecíficos que comprenden un Dominio Fc de inmunoglobulina (diacuerpos Fc monovalentes biespecíficos) y se componen de tres cadenas de polipéptidos y las cuales poseen al menos un sitio que une de manera especifica a un epítopo de gpA33 y un sitio que une de manera especifica a un epítopo de CD3 (es decir, un diacuerpo Fc monovalente biespecífico de gpA33 x CD3). Los diacuerpos monovalentes biespecíficos y diacuerpos Fc monovalentes biespecíficos de la presente son capaces de unión simultánea a gpA33 y CD3. La solicitud se dirige a composiciones farmacéuticas que contienen tales diacuerpos monovalentes biespecíficos o tales diacuerpos Fc monovalentes biespecíficos. Además, se dirige a métodos para el uso de tales diacuerpos en el tratamiento de cáncer y otras enfermedades y padecimientos.This is directed to bispecific monovalent diabodies that comprise two polypeptide chains and which have at least one site that specifically binds a CD3 epitope and a site that specifically binds to a gpA33 epitope (i.e., a bispecific monovalent diabody of gpA33 x CD3). This is also directed to bispecific monovalent diabodies that comprise an immunoglobulin Fc Domain (bispecific monovalent Fc diabodies) and are composed of three chains of polypeptides and which possess at least one site that specifically binds an epitope of gpA33 and a site that specifically binds a CD3 epitope (i.e., a bispecific monovalent Fc diabody of gpA33 x CD3). The bispecific monovalent diabodies and bispecific monovalent monobial diabodies of the present are capable of simultaneous binding to gpA33 and CD3. The request is directed to pharmaceutical compositions containing such bispecific monovalent diabodies or such bispecific monovalent Fc diabodies. In addition, it addresses methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869528P | 2013-08-23 | 2013-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097404A1 true AR097404A1 (en) | 2016-03-09 |
Family
ID=56131694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103130A AR097404A1 (en) | 2013-08-23 | 2014-08-20 | MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN GPA33 AND CD3, AND USES OF THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR097404A1 (en) |
-
2014
- 2014-08-20 AR ARP140103130A patent/AR097404A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16096342A (en) | COVALENTLY LINKED DIACBODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE OF THE SAME | |
| MX2016001738A (en) | BI-SPECIFIC MONOVALENT DIACUMS THAT ARE ABLE TO LINK TO GPA33 AND CD3, AND THEIR USES. | |
| MX2016001741A (en) | BIO-SPECIFIC MONOVALENT FC DIACUERPOS THAT ARE ABLE TO JOIN CD32B AND CD79B AND USES OF THE SAME. | |
| ECSP18011248A (en) | BISPECIFIC MONOVALENT DIACBODIES THAT ARE CAPABLE OF BINDING AND USING B7-H3 AND CD3 | |
| CO2018002360A2 (en) | Bispecific Antibodies Against Human A-beta and Human Transferrin Receptor and Methods of Use | |
| CO2018005932A2 (en) | Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| BR112018071307A2 (en) | human cd40 binding agonist antibodies and uses thereof | |
| EA201692504A1 (en) | TRISPECIFIC BINDING MOLECULES AND METHODS OF THEIR APPLICATION | |
| MX2016012094A (en) | COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT. | |
| BR112019000970A2 (en) | multispecific antigen binding proteins and methods of use thereof | |
| BR112017003194B8 (en) | ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO HUMAN LAG3, COMPOSITION, AND, USE OF THE ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF THESE AND THE COMPOSITION | |
| BR112016030740A2 (en) | bispecific heterodimeric bodies and their uses | |
| MX2018007288A (en) | NEUTRALIZING ANTIBODIES FOR THE HUMAN IMMUNODEFICIENCY VIRUS. | |
| AR087601A1 (en) | ANTIBODIES WITHOUT FC THAT INCLUDE TWO FAB FRAGMENTS AND METHODS OF USE | |
| MX2019007554A (en) | BINDING PROTEINS TO THE ANTI-NEUROPYLIN ANTIGEN, AND THEIR METHODS OF USE. | |
| NI201800017A (en) | ANTI-CD154 ANTIBODIES AND METHODS OF USE OF THEM | |
| CO2018012497A2 (en) | Interferon beta antibodies and uses thereof | |
| MX2024005841A (en) | Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders. | |
| AR097404A1 (en) | MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN GPA33 AND CD3, AND USES OF THE SAME | |
| AR111000A1 (en) | BISPECIFIC UNION MOLECULES THAT ARE ABLE TO JOIN CD137 AND TUMOR ANTIGENS, AND USES OF THE SAME | |
| UY35697A (en) | FC BI-SPECIFIC MONOVALENT SPECIFICS THAT ARE ABLE TO JOIN CD32B AND CD79B AND USES OF MY SMOS | |
| AR105714A1 (en) | MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN B7-H3 AND CD3, AND USES OF THE SAME | |
| EA202090586A2 (en) | TRANSPECIFIC BINDING MOLECULES AND METHODS FOR THEIR APPLICATION | |
| ECSP17016757A (en) | ANTI-LAG3 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS | |
| AR099798A1 (en) | METHODS AND COMPOSITIONS OF ANTIBODIES FOR TUMOR TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |